Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast

Annals of Surgical Oncology

Volumn 14, Issue 7, 2007, Pages 2097-2104

  De Roos, Marnix A ^a   Van Der Vegt, Bert ^a   De Vries, Jaap ^a   Wesseling, Jelle ^a   De Bock, Geertruida H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biological markers; Breast neoplasm; Ductal carcinoma in situ; Immunohistochemistry; Screening

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; RISK; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN D1; FEMALE; GENES, ERBB-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MASS SCREENING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250856262     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9395-7     Document Type: Article

References (31)

1. Voogd AC, Crommelin MA, Repelaer van Driel OJ, Nolthenius-Puylaart MC, van der Heijden LH, Coebergh JW. Trends in incidence and treatment of ductal carcinoma in situ of the breast in southeast Netherlands. Ned Tijdschr Geneeskd 2000; 14:659-63
2. Levi F, Te VC, Randimbison L, La Vecchia C. Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 1997; 33:903-6
3. Ernster V, Barclay J, Kerlikowske K, Grady D, Henderson I. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913-8
4. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94:1546-54
5. Jatoi I, Baum M. Mammographically detected ductal carcinoma in situ: are we over-diagnosing breast cancer? Surgery 1995; 118:188-21
6. Thornton H. Consequences of breast screening. Lancet 2000; 356:1033
7. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997; 127:1023-8
8. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76:1197-1200
9. Eusebi V, Foschini MP, Cook MG, Berrino F, Azzopardi JG. Long-term follow-up of in situ carcinoma of he breast with special emphasis on clinging carcinoma. Semin Diagn Pathol 1989; 6:165-73
10. Fisher E, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight year update of Protocol B-17. Cancer 1999; 86:429-38
11. Julien JP, Bijker N, Fentiman I, et al. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000; 355:528-33
12. Evans A, Pinder S, Ellis I, et al. Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 1994; 191:237-40
13. Stomper P, Conolly J. Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. Am J Radiol 1992; 159:483-5
14. de Roos MA, Pijnappel RM, Post WJ, de Vries J, Baas PC, Groote AD. Correlation between imaging and pathology of ductal carcinoma in situ of the breast. World J Surg Oncol 2004; 2:4
15. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11:167-80
16. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995; 345:1154-7
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7
18. Vos CB, Ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 1999; 189:279-84
19. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003; 39:1746-54
20. Meijnen Ph, Peterse JL, Oldenburg LA, Woerdeman LA, Rutgers EJ. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur J Surg Oncol 2005; 31:833-9
21. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected ductal carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618-24
22. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999; 85:616-28
23. Kerlikowske K, Mollarino A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003; 95:1692-1702
24. Walker RA, Dearing SJ, Brown LA. Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 1999; 30:943-8
25. Idvall I, Andersson C, Fallenius G, et al. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening. Acta Oncol 2001; 40:653-9
26. Evans AJ, Pinder SE, Ellis IO, Wilson AR. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 2001; 8:149-51
27. Kessar P, Perry N, Vinnicombe SJ, Hussain HK, Carpenter R, Wells CA. How significant is detection of ductal carcinoma in situ in a breast screening programme? Clin Radiol 2002; 57:807-14
28. Ho GH, Calvano JE, Bisogna M, et al. In microdissected ductal carcinoma in situ, Her-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 2000; 89:2153-60
29. Mack L, Kerkvliet N, Doig G, O'Malley FP. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erbB-2, bcl-2, and ki-67. Hum Pathol 1997; 28:974-9
30. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995; 75:2123-31
31. Boland GP, Knox WF, Bundred NJ. Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech 2002; 59:3-11